News and Trends 19 Jul 2022 Good news for Destiny Pharma’s nasal gel to combat life-threatening infections Clinical stage biotech company, Destiny Pharma, announced today (July 19) a positive update from the U.S. Food and Drug Administration (FDA) on its XF-73 nasal gel phase 3 development plans. The FDA has clarified the phase 3 and U.S. registration pathway for the gel for the prevention of post-surgical staphylococcal infections, and this feedback enables […] July 19, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2022 Oncoshot raises cash to speed up clinical trial enrolment with AI The Singapore-based startup Oncoshot has raised an undisclosed amount in a pre-Series A round to drive the expansion of its artificial intelligence (AI)-driven clinical trial enrolment technology into Australia and India. The round, led by the tech-focused venture capital firm MassMutual Ventures, allows Oncoshot to pursue its mission of eliminating barriers to the recruitment of […] July 15, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Orthox green light for knee cartilage repair clinical trial Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, can start its FFLEX (FibroFix cartilage repair experience) study. The company has received a Letter of No Objection from the UK’s MHRA, enabling the start of the study. The study, which is also supported by funding […] July 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab Drug development is a lengthy and costly process that takes at least 10 years on average from drug discovery to commercialization, requiring billions of dollars in investment. However, over 90% of new drugs that are tested in clinical trials fail. Organoids — three-dimensional, patient-derived mini-organs in a dish — offer a solution to this challenge. […] July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Progress for hearing preservation trial after Australian approval granted Approval has been granted by the Australian authorities to allow a French company to progress with a clinical trial testing cochlear implants. Montpellier-based Sensorion will start its proof of concept trial of SENS-401, a drug candidate that aims to protect and preserve inner ear tissue from damage. Sensorion is a biotech company specializing in the […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 LG Chem renews license triggering $2M payment to Avacta South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal fee to UK-based oncology drug company Avacta Group plc. of $2 million. Avacta develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms. Under the terms of the agreement, LG Chem has the exclusive rights to develop […] June 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Encouraging results from respiratory diseases vaccine trial A biopharmaceutical company developing vaccines against infectious diseases has announced positive results for people with life threatening respiratory diseases. Icosavax says that in an interim phase 1/1b trial its vaccine IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no […] June 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Biogen, citing insurance challenges, shutters one of its Aduhelm studies A company says it was forced to end an observational trial of Alzheimer’s drug, Aduhelm, after a ruling by US federal insurance program, Medicare. Biogen said a recent coverage decision by Medicare has forced it to abandon the trial of the drug after enrolling just 29 participants. The company said it made the decision to […] June 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Osivax gets €10M influenza vaccine grant A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2022 Zealand Pharma’s drug for rare metabolic disease smashes phase III After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […] May 20, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2022 Reforms of EU Clinical Trial Regulations Bring Cautious Optimism The EU’s clinical trial regulations received a major overhaul at the end of January 2022 to make trials easier to run across EU member states. It may bring some short-term chaos, industry insiders say, but down the road it is likely to pay off. At the start of February, the EU’s new Clinical Trials Regulation […] February 8, 2022 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email